Fundz

Who to call at Kernal Biologics, and when

Fundz watches for the moments Kernal Biologics starts buying, and tells you who to reach.

  • An alert the day Kernal Biologics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kernal Biologics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kernal Biologics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Kernal Bio Establishes Partnership with IFLI to Advance KR-402 for Follicular Lymphoma Treatment.

Nov 17, 2026

Contract Type

partnership

CambridgeBiotechnologyHealthcareHealth Careresearch

Description

Kernal Bio announces a strategic partnership with the Institute for Follicular Lymphoma Innovation (IFLI) to support the development of KR-402, a treatment for follicular lymphoma. This collaboration includes an investment aimed at accelerating preclinical development and brings new leadership appointments.

Quick answer

Kernal Bio Establishes Partnership with IFLI to Advance KR-402 for Follicular Lymphoma Treatment. (November 17, 2026). Kernal Biologics is based in Cambridge, Massachusetts, United States.

What agreement did Kernal Biologics announce on November 17, 2026?
Kernal Bio announces a strategic partnership with the Institute for Follicular Lymphoma Innovation (IFLI) to support the development of KR-402, a treatment for follicular lymphoma. This collaboration includes an investment aimed at accelerating preclinical development and brings new leadership appointments.
What does Kernal Biologics do?
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology.
Where is Kernal Biologics based?
Kernal Biologics is based in Cambridge, Massachusetts, United States.
Which similar companies announced agreements around the same time?
Aarvik Therapeutics (November 3, 2026), Ocugen (November 10, 2026), AbbVie Inc. (November 3, 2026) and Cognito Therapeutics (October 27, 2026) also announced agreements within 45 days of Kernal Biologics.

Source: Fundz verified event record.

Other recent agreements in Healthcare and research

Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.

Company Information

Company

Kernal Biologics

Location

700 MAIN STREET

Cambridge, Massachusetts, United States

About

Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three FDA-approved therapies and over 120 patents. With support from leading investors — including Hummingbird Ventures, Amgen Ventures, Y Combinator, FoundersX, and HBM — Kernal Bio is transforming the future of cell therapy design and delivery.

Related People

Yusuf
Senior decision-maker at this company
••••••••@••••••••

See Yusuf's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Kernal Biologics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Kernal Biologics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.